ACBD5 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ACBD5 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AFAP1L2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AFAP1L2 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL is altered in 0.94% of thyroid gland medullary carcinoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCDC6 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CEP43 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEP43 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERC1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERC1 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GOLGA5 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GOLGA5 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HOOK3 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HOOK3 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIAA1217 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1217 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIF5B is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIF5B status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is altered in 0.63% of thyroid gland medullary carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NCOA4 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NCOA4 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPFIBP2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPFIBP2 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PRKAR1A is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKAR1A status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 70.48% of thyroid gland medullary carcinoma patients [2].

RET is an inclusion eligibility criterion in 7 clinical trials for thyroid gland medullary carcinoma, of which 6 are open and 1 is closed. Of the trials that contain RET status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Pralsetinib, selpercatinib, and vandetanib have evidence of efficacy in patients with RET mutation in thyroid gland medullary carcinoma [3].

RUFY1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RUFY1 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TFG is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRIM27 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRIM27 status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].